Adaptive Biotechnologies Corp (NASDAQ: ADPT) on Tuesday, plunged -4.24% from the previous trading day, before settling in for the closing price of $11.55. Within the past 52 weeks, ADPT’s price has moved between $3.85 and $12.43.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -1.51% annually for the last half of the decade. The company achieved an average annual earnings per share of 21.47%. With a float of $144.91 million, this company’s outstanding shares have now reached $151.92 million.
In an organization with 619 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 61.06%, operating margin of -71.5%, and the pretax margin is -74.86%.
Adaptive Biotechnologies Corp (ADPT) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Adaptive Biotechnologies Corp is 4.61%, while institutional ownership is 90.52%. The most recent insider transaction that took place on May 16 ’25, was worth 17,149. In this transaction Chief Financial Officer of this company sold 1,929 shares at a rate of $8.89, taking the stock ownership to the 277,396 shares. Before that another transaction happened on May 01 ’25, when Company’s Chief Scientific Officer sold 68,412 for $7.35, making the entire transaction worth $502,828. This insider now owns 1,279,524 shares in total.
Adaptive Biotechnologies Corp (ADPT) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 21.47% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 30.19% during the next five years compared to -1.51% drop over the previous five years of trading.
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Trading Performance Indicators
Adaptive Biotechnologies Corp (ADPT) is currently performing well based on its current performance indicators. A quick ratio of 2.82 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.96, a number that is poised to hit -0.24 in the next quarter and is forecasted to reach -0.64 in one year’s time.
Technical Analysis of Adaptive Biotechnologies Corp (ADPT)
Let’s dig in a bit further. During the last 5-days, its volume was 1.82 million. That was inferior than the volume of 2.04 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 30.21%.
During the past 100 days, Adaptive Biotechnologies Corp’s (ADPT) raw stochastic average was set at 77.81%, which indicates a significant increase from 24.52% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.61 in the past 14 days, which was higher than the 0.60 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.25, while its 200-day Moving Average is $7.56. However, in the short run, Adaptive Biotechnologies Corp’s stock first resistance to watch stands at $11.47. Second resistance stands at $11.88. The third major resistance level sits at $12.11. If the price goes on to break the first support level at $10.83, it is likely to go to the next support level at $10.60. The third support level lies at $10.19 if the price breaches the second support level.
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Key Stats
Market capitalization of the company is 1.68 billion based on 151,917K outstanding shares. Right now, sales total 178,960 K and income totals -159,490 K. The company made 52,440 K in profit during its latest quarter, and -29,850 K in sales during its previous quarter.
